The BHF FAMOUS NSTEMI Trial For the FAMOUS NSTEMI Investigators ESC Hotline for Myocardial...

The BHF FAMOUS NSTEMI Trial

For the FAMOUS NSTEMI InvestigatorsESC Hotline for Myocardial Infarction, 1 Sep 2014

J. Layland, K.G. Oldroyd, N. Curzen, A. Sood, K. Balachandran, R. Das, S. Junejo, N. Ahmed, M. Lee, A. Shaukat, A. O'Donnell, J. Nam, A. Briggs, R. Henderson, A. McConnachie, C. Berry

Body text

Disclosures

British Heart Foundation Project Grant.

St Jude Medical provided the pressure wires to the 6 hospitals that participated in this study.

Investigators: CB, NC, KGO are Consultants / Speakers to St Jude Medical and/or Volcano Corp.

Institutional research agreement between St Jude Medical and University of Glasgow / CB.

Travel support from Pfizer.

Natural history & prognosis after NSTEMI

• Cardiac events Coronary - Spontaneous plaque rupture

- Longer term remodelling

Myocardial - Sudden death & heart failure

• Non-cardiac events - co-morbidity

Decision-makingAnatomy vs. Anatomy + Function

• Ad hoc diagnostic angiography Treatment decisions are based on visual interpretation of the angiogram.

• FFRClass I recommendation in stable CAD

No guideline recommendation in ACS, evidence is lacking. ESC Hotline 1 Sep 2014

Rationale: FFR in NSTEMI

ESC Hotline 1 Sep 2014

• Ischaemia hypothesis =

Lesion-level ischaemia predicts coronary risk.

• FFR ischaemic threshold = 0.80 specifies OMT vs. PCI vs. CABG

• FFR - Unnecessary PCIs and procedure-related MI will be reduced.

• The validity of FFR in culprit and non-culprit arteries is uncertain.

Berry C et al Am Heart J 2013; NCT01764334

FAMOUS-NSTEMI trial• Hypothesis

Routine FFR is feasible in NSTEMI patients and adds diagnostic, clinical and economic benefits, compared to standard angiography-guided management.

• Objective

Developmental trial for evidence-synthesis to inform a definitive health outcome trial.


FAMOUS-NSTEMIOutcomes

• Primary outcomeThe proportion of patients allocated to medical management only at baseline in each group.

• Secondary outcomes1. Feasibility & safety of routine FFR.

2. Relationship of FFR vs. stenosis severity.

3. MACE – cardiac death, non-fatal MI, heart failure.

4. Resource use

5. Quality of lifeESC Hotline 1 Sep 2014

Golden Jubilee, GlasgowHairmyres

Southampton

Freeman

Royal Blackburn

Sunderland

Screened

Consent

Screenedn = 444

Oct. 2011

May 2013

n = 174n = 176

350Randomise


Registryn = 503

0

20

40

60

80

100FFR-Guided Angiography-Guided

GRACE Score for Death/MI 6 months= 146

Time from event to angiography3 (2,5) days

Radial access – 90%

%

Baseline characteristics



FFR vs. Stenosis Severity

Stenosis severity, %

350 patients706 lesions≥ 30% severity

FFR successful100% of patients>99% lesions2 wire dissections

FFR

FFR-disclosureTreatment change

Initial treatment

Change post-FFR

Final decision

FFR treatment change ~ 22% of patients

Primary outcome% medical therapy at baseline

0

5

10

15

20

25

Post-Randomisation 1-year

FFR-guided Angiography-guided

%

p = 0.022 p = 0.054

In-hospital costs were similar

22.7

13.2


% medical therapy onlyBaseline & 1 year

0

5

10

15

20

25

Post-Randomisation 1-year

FFR-guided Angiography-guided

%

p = 0.022 p = 0.054

Quality of life was similarESC Hotline 1 Sep 2014

All MACEFFR-guided vs. Angio-guided

Angiography – guidedn = 15 (8.6%)

MACE1 year

FFR – guidedn = 14 (8.0%)

Log Rankp = 0.79

Days


Procedure-related MIFFR-guided vs. Angio-guided

Type 4 - Procedure-related MI, 1 year

Angiography - guided

FFR - guided

p = 0.12

Myocardial infarctionFFR-guided vs. Angio-guided

Type 4 MIProcedure-related

Types 1-3 MISpontaneous


FFR - guided

FFR - guided


p = 0.12 p = 0.56

Summary1. Trial popn represented > 40% of NSTEMI

patients who gave consent.

2. FFR was successful in 100% of patients

and safe (2 dissections in 706 lesions).

3. Randomisation & adherence to protocol were successful.

4. FFR-disclosure commonly changed therapy, PCIs & Type 4 MIs and was cost neutral.

5. Health outcomes were similar.

Conclusions1. FFR is feasible, safe and reduces PCI &

procedure MI in NSTEMI.

2. No difference in health outcomes vs. standard care, but under-powered.

3. FFR-guided group outcomes

Most MACE not related to FFR disclosure.

Late MACE Natural history of CAD progression.

4. A large trial is needed to assess health outcomes & cost-effectiveness.

Thank you.Patients, staff, funders.

FAMOUS-NSTEMI

European Heart Journal 1 Sept. 2014 on-line

Clinical Event CommitteeDr Andrew Hannah, Dr Andrew Stewart

Data & Safety Monitoring CommitteeProf John Norrie, Prof Andrew Clark, Dr Saqib Chowdhary

The BHF FAMOUS NSTEMI Trial For the FAMOUS NSTEMI Investigators ESC Hotline for Myocardial...

Documents

Transcript of The BHF FAMOUS NSTEMI Trial For the FAMOUS NSTEMI Investigators ESC Hotline for Myocardial...